Quinquaud's folliculitis decalvans

Summary

Quinquaud’s folliculitis decalvans (MONDO:0018103) is a disease and 2 clinical trials. Top therapeutic interventions include adalimumab. A subtype of alopecia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Phenotypes (HPO): 7
• Clinical trials: 2

Clinical features

Signs & symptoms

Clinical features (HPO)

7 HPO clinical features (Orphanet curated; top 7 by frequency):

HPO ID	Term	Frequency
HP:0001581	Recurrent skin infections	Very frequent (80-99%)
HP:0001595	Abnormality of the hair	Very frequent (80-99%)
HP:0002232	Patchy alopecia	Very frequent (80-99%)
HP:0004552	Scarring alopecia of scalp	Very frequent (80-99%)
HP:0010783	Erythema	Very frequent (80-99%)
HP:0200039	Pustule	Very frequent (80-99%)
HP:0100699	Scarring	Frequent (30-79%)

Identifiers

Disease identifiers

Field	Value
Canonical name	Quinquaud’s folliculitis decalvans
Mondo ID	MONDO:0018103
Orphanet	346
ICD-11	1454811046
SNOMED CT	53593008
UMLS	C2608043
MedGen	750617
GARD	0000373
Is cancer (heuristic)	no

Also known as: folliculitis decalvans · Quinquaud’s decalvans folliculitis · Quinquaud’s disease · Quinquaud’s disease

Disease family

This is a subtype of alopecia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › disorder of pilosebaceous unit › hair anomaly › alopecia › Quinquaud’s folliculitis decalvans

Related subtypes (25): alopecia, isolated, telogen effluvium, alopecia areata, chemotherapy-induced alopecia, alopecia mucinosa, atrichia with papular lesions, loose anagen syndrome, Satoyoshi syndrome, alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome, hereditary hypotrichosis with recurrent skin vesicles, alopecia antibody deficiency, pseudopelade of Brocq, frontal fibrosing alopecia, Graham Little-Piccardi-Lassueur syndrome, lichen planopilaris, hypotrichosis simplex, alopecia totalis, hypotrichosis simplex of the scalp, endocrine alopecia, alopecia universalis onychodystrophy vitiligo, central centrifugal cicatricial alopecia, ectodermal dysplasia alopecia preaxial polydactyly, Slti-Salem syndrome, microcephaly sparse hair intellectual disability seizures, alopecia universalis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07268534	PHASE2	NOT_YET_RECRUITING	Biologics in Folliculitis Decalvans : an Adaptative Trial Research
NCT02157688	Not specified	COMPLETED	Impact of Staphylococcus Aureus on Folliculitis Decalvans

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ADALIMUMAB	4	1